Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel,…
| Periodo | 2026-11 | 2026-08 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | — | $-0.16 | $-0.22 |
| Estimado | $0.01 | $0.28 | $-0.19 | $-0.18 |
| Sorpresa | — | — | +15.8% | -22.2% |
| Métrica | LEGN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 61.4% | 57.4% | +4.0% |
| Operating Margin | -13.3% | -34.4% | +21.1% |
| Net Margin | -28.9% | -32.5% | +3.6% |
| FCF Margin | -12.5% | -12.6% | +0.1% |
| ROE | -29.6% | -39.2% | +9.6% |
| ROA | -17.1% | -30.9% | +13.8% |
| Current Ratio | 1.96 | 2.73 | -0.77 |
| Debt / Equity | 0.00 | 0.28 | -0.28 |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -17.1% | — |
| ✗Flujo de caja operativo positivo | −$100M | −$144M |
| ✗Rentabilidad sobre activos al alza | -17.1% | -10.6% |
| ✓Caja operativa/activos supera al ROA | -5.8% | ROA -17.1% |
| ✓Menos deuda a largo plazo | 0.0% | 18.0% |
| ✗Mejor liquidez (ratio corriente) | 1.96 | 4.62 |
| ✗Sin aumentar el nº de acciones | 369M | 366M |
| ✗Margen bruto al alza | 61.4% | 65.5% |
| ✓Rotación de activos al alza | 0.59 | 0.38 |
| Calidad del negocio | FY25 |
|---|---|
| ✗Margen FCF > 10 % | -12.5% |
| ✗ROCE > 10 % | -12.4% |
| ✓Ventas > 5 %/año (3 años) | 106.4% |
| ✓Deuda neta/EBITDA < 3x | Caja neta |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 43.1% |
Legend Biotech Corp cotiza a 18.48 USD y tiene una capitalización bursátil de $3.6B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud